Ignite Creation Date:
2025-12-24 @ 6:49 PM
Ignite Modification Date:
2026-01-04 @ 10:53 AM
Study NCT ID:
NCT01905657
Status:
COMPLETED
Last Update Posted:
2021-10-06
First Post:
2013-07-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-08-09
Start Date Type:
ACTUAL
Primary Completion Date:
2015-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2013-07-18
First Submit QC Date:
None
Study First Post Date:
2013-07-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-09-15
Results First Submit QC Date:
None
Results First Post Date:
2017-01-18
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-13
Last Update Post Date:
2021-10-06
Last Update Post Date Type:
ACTUAL